A novel physiologically realistic microfluidic in-vitro blood-brain barrier model

Information

  • Research Project
  • 8469865
  • ApplicationId
    8469865
  • Core Project Number
    R44GM087129
  • Full Project Number
    5R44GM087129-03
  • Serial Number
    087129
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    4/1/2009 - 15 years ago
  • Project End Date
    5/31/2015 - 9 years ago
  • Program Officer Name
    COLE, ALISON E.
  • Budget Start Date
    6/1/2013 - 11 years ago
  • Budget End Date
    5/31/2015 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    03
  • Suffix
  • Award Notice Date
    5/17/2013 - 11 years ago
Organizations

A novel physiologically realistic microfluidic in-vitro blood-brain barrier model

DESCRIPTION (provided by applicant): The overall objective of this study is to develop a novel in vitro microfluidic platform to test a drug or delivery vehicle's ability to permeate the Blood-Brain Barrier (BBB). In contrast to current in-vitro models, our proposed device, SIM-BBB, comprises of a microfluidic two-compartment chamber. The chamber is designed in such a way as to permit visualization-friendly evaluation of transport/permeation under appropriate microcirculatory size and flow conditions, while simultaneously simplifying device fabrication. The apical side is seeded with endothelial cells and the basolateral side supports glial cell co-cultures. The increased physiological realism substantially improves BBB characteristics including formation of tight junctions and expression of relevant transporters. The new platform offers greater throughput, increased library coverage, lower cost, rapid turnaround times and increased mechanistic knowledge benefiting drug discovery efforts. In Phase I, the first generation microfluidic SIM-BBB device was designed and fabricated using soft lithography. Brain endothelial cells were cultured in the microfluidic constructs with a perfusate of astrocyte conditioned media. Biochemical analysis showed upregulation of tight junction molecules while optical analysis showed intactness of the BBB in the microfluidic device. Finally, transporters assay was successfully demonstrated in the device. Phase II efforts will focus on optimization of the microfluidic device for enhanced physiological fidelity. Electrodes will be integrated for non-visual monitoring of the endothelial cell layers and tight junction formation via trans-endothelial electrical resistance (TEER) measurements. Finally, the developed technology will be demonstrated for diverse applications including drug penetration studies and leukocyte migration under inflammatory conditions. A multi-disciplinary partnership with expertise in engineering and biology has been assembled for successful completion of the project.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    619024
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:619024\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CFD RESEARCH CORPORATION
  • Organization Department
  • Organization DUNS
    185169620
  • Organization City
    HUNTSVILLE
  • Organization State
    AL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    358062922
  • Organization District
    UNITED STATES